AstroGenetix News

ASTROGENETIX PERFORMS DRUG DEVELOPMENT IN MICROGRAVITY

SHaywood — Wed, 26 May 2010 09:23:43 -0400

Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

ASTROGENETIX NARROWS IN ON MRSA VIRULENCE ONBOARD DISCOVERY

SHaywood — Tue, 06 Apr 2010 10:28:59 -0400

Astronauts on board Space Shuttle Discovery (STS-131) activated an experiment this morning as part of the ninth scientific payload for Astrogenetix, an Austin, Texas-based commercial biotech company. Astrogenetix is conducting the International Space Station National Laboratory Pathfinder Vaccine (NLP-V) missions to take advantage of the unique conditions of microgravity to uncover changes in bacteria that can be targeted to create new vaccines and therapeutics.

ASTROGENETIX CONTINUES MRSA VACCINE DEVELOPMENT ONBOARD ENDEAVOR

SHaywood — Mon, 08 Feb 2010 15:51:44 -0500

Space Shuttle Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

AUSTIN-BASED BIOTECH COMPANY’S VACCINE RESEARCH TO CONTINUE ON ATLANTIS MISSION

SHaywood — Wed, 18 Nov 2009 11:16:46 -0500

For the fourth time this year, NASA’s Shuttle fleet is carrying a series of experiments being conducted by Austin-based Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

SPACE SHUTTLE DISCOVERY TO CARRY VACCINE RESEARCH ALONG WITH INTERNATIONAL SPACE STATION EQUIPMENT

SHaywood — Wed, 26 Aug 2009 00:36:36 -0400

Astrogenetix Works with NASA to Use Microgravity to Develop New Medicines

Along with supply and equipment cargo bound for the International Space Station, Space Shuttle Discovery STS-128 will carry an additional scientific payload being conducted by Austin-based Astrogenetix, the first commercial space company to use microgravity to discover the foundation of new medicines.

ASTROTECH STATEMENT ON THE 40TH ANNIVERSARY OF APOLLO 11 MOON LANDING

SHaywood — Mon, 20 Jul 2009 17:24:41 -0400

Astrotech Corporation (NASDAQ: ASTC) Chairman and Chief Executive Officer, Thomas B. Pickens III today issued the following statement regarding the 40th anniversary of the first moon landing by Apollo 11.

ASTROGENETIX ADVANCES MRSA RESEARCH ON HUBBLE FLIGHT

SHaywood — Fri, 15 May 2009 09:47:42 -0400

Astrogenetix, Inc., a subsidiary of the Astrotech Corporation (Nasdaq:ASTC), today announced preliminary findings from its microgravity-based virulence survey aboard Shuttle Discovery (STS-119) launched on March 15, 2009. These results showed that methicillin-resistant Staphylococcus aureus (MRSA) and other microbes exhibit altered phenotypical responses during spaceflight.

ASTROGENETIX TO CONDUCT MRSA RESEARCH ON SHUTTLE MISSION

admin — Thu, 26 Mar 2009 15:52:07 -0400

Astrogenetix, Inc., a subsidiary of the Astrotech Corporation, today announced it is conducting novel pharmaceutical research aboard Shuttle Discovery (STS-119) on NASA mission 15A scheduled to launch this evening and destined for the International Space Station (ISS).

SPACEHAB FINALIZES AGREEMENT WITH NASA

testcontenteditor — Fri, 27 Feb 2009 15:48:06 -0500

SPACEHAB Incorporated, (NASDAQ: SPAB), today announced that the company has finalized a Space Act Agreement with the National Aeronautics and Space Administration (NASA) for use of the International Space Station (ISS), a designated U.S. National Laboratory, for research, development and industrial processing purposes. This agreement marks the beginning of SPACEHAB's new subsidiary BioSpace Technologies, Inc.

SEND VALIDATION OF SALMONELLA VACCINE TARGET TO THE SPACE STATION

admin — Wed, 18 Mar 2009 15:54:03 -0400

A partnership between Space Florida and SPACEHAB’s new biotech subsidiary BioSpace Technologies Inc. is paving the way to develop multiple vaccine targets on the International Space Station (ISS).

SPACEHAB CHIEF SPEAKS AT U.S. HOUSE

admin — Fri, 13 Mar 2009 13:34:41 -0400

SPACEHAB Incorporated, (NASDAQ: SPAB), a provider of commercial space services, today announced that Thomas B. Pickens, III, SPACEHAB Chairman and Chief Executive Officer, served as a key witness today in a hearing with the U.S. House of Representatives Committee on Science and Technology, Subcommittee on Space and Aeronautics, regarding NASA's International Space Station (ISS) Program: Status and Issues.

SPACEHAB TEAMS WITH STATE OF FLORIDA

admin — Fri, 13 Mar 2009 13:42:43 -0400

SPACEHAB Incorporated, (NASDAQ: SPAB), a provider of commercial space services, along with Florida Governor Charlie Crist, recently announced the Company's partnership with the state of Florida to establish a space-based, biotech corridor that stretches from the International Space Station (ISS) to Earth-based Florida facilities and resources such as the Space Life Sciences Lab at NASA's John F. Kennedy Space Center (KSC).

SPACEHAB ANNOUNCES FORMATION OF COUNCIL

admin — Tue, 17 Mar 2009 10:40:19 -0400

SPACEHAB Incorporated, (NASDAQ: SPAB), a provider of commercial space services, today announced the formation of a new Science Advisory Council, an elite team of scientists, physicians, and microgravity specialists who provide strategic guidance and technical insight as the Company advances its identified microgravity processing initiatives through its new subsidiary, SPACEHAB Microgravity Sciences, Inc.